Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alphabet Inc Class A (GOOGL) vs BIO-TECHNE Corp (TECH) Price & Performance

Alphabet Inc Class ATrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Alphabet Inc Class A vs BIO-TECHNE Corp — how do they compare? Alphabet Inc Class A trades at $345 (market cap $4.36T), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Alphabet Inc Class A is far larger — about 387.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.

GOOGLTECH
Market Cap
$4.36T$11.24B
Sector
MediaHealth
52-Week High
$402.62$72.29
52-Week Low
$199.32$43.31
Enterprise Value
$4.25T$11.32B
Dividend Yield
0.25%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alphabet Inc Class A

Alphabet (GOOGL) trades at $357.52, up 0.91% with strong technical momentum as it approaches resistance near $359. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $9.11 versus $2.87, revenue growth from $402.84B in 2025 to projected $445.9B in 2026, and improving profit margins. Recent developments include YouTube subscription price increases and strategic AI partnerships with Intel and Anthropic, positioning the company for continued growth in the digital advertising and cloud computing sectors.

Alphabet presents a compelling investment case with 85% analyst buy ratings and a $426.28 consensus price target representing 19% upside potential. Key opportunities include AI-driven revenue growth and expanding cloud market share, while risks involve antitrust scrutiny and competitive pressures in digital advertising. The stock's current valuation at 17.94 P/E appears reasonable given the company's strong earnings trajectory and market leadership position.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.

Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alphabet Inc Class A

Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.

Read more on GOOGL

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH